A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression.

Randomized, double-blind, placebo-controlled trials were developed to draw rather unbiased conclusions regarding the efficacy of antidepressants in the treatment of a major depressive episode (internal validity), mostly with the purpose of formal approval of new compounds in this indication. However, at the same time, data suggest that the very process of randomization and blinded administrations of placebo will have a significant impact on the efficacy of the antidepressant tested and therefore may limit the external validity of results obtained from this type of studies. Therefore, there is an urgent need to systematically study the impact of randomization/placebo control/blinding on patient population, efficacy, tolerability, and external validity in the psychopharmacological treatment of patients with a major depressive episode. To develop a study design that allows the systematic exploration of the impact of trial design on characteristics of included patient population and outcome. We propose a study design including sample size calculation and statistical analysis in which patients with a major depressive episode are randomized to 3 distinct study designs that differ with regard to control, randomization, and blindness. The results of the proposed study design may have substantial consequences when it comes to how to best interpret the results of traditional randomized, double-blind, placebo-controlled trials in the acute treatment of major depressive disorder. Furthermore, they may lead to the implementation of new study designs that may be more suitable for assessing the effectiveness of new antidepressant compounds in everyday clinical practice.

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

Dr. Severus declares that he has received speaker honoraria from Servier and Roche in the past 3 years. In addition Dr. Severus is Co-Chair of the joint ISBD-IGSLI lithium task force.Cathrin Sauer has no conflicts of interest.Prof. Michael Bauer declares that he was employed on an advisory board of Allergan, Aristo, Boehringer-Ingelheim, Janssen, Lundbeck, neuraxpharm, Otsuka, Servier, and Takeda, and has received lecture fees from AstraZeneca, GlaxoSmithKline, Lilly, neuraxpharm, Pfizer, and Servier in the past 3 years. His institution has received research grants from Deutsche Forschungsgemeinschaft (DFG), and Bundesministeriums für Bildung und Forschung (BMBF) in the past 3 years.Dr. Ostacher has been consultant to Acadia Pharmaceuticals, Genomind, Janssen/Johnson&Johnson, Lundbeck, Otsuka, Sage Therapeutics, Sunovion, and Supernus Pharmaceuticals, and has received research funding from Palo Alto Health Sciences.Prof. Ion-George Anghelescu: Speaker or scientific advisor honorariar for: Aristo, Bioehringer-Ingelheim, Janssen, Lundbeck, Otsuka, Schwabe, Trommsdorff.